Ieq Capital LLC lessened its holdings in shares of 10x Genomics (NASDAQ:TXG – Free Report) by 26.4% during the third quarter, HoldingsChannel reports. The fund owned 387,484 shares of the company’s stock after selling 138,906 shares during the period. Ieq Capital LLC’s holdings in 10x Genomics were worth $35,013,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Quantinno Capital Management LP raised its position in 10x Genomics by 16.0% in the first quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock worth $114,892,000 after acquiring an additional 744,558 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of 10x Genomics by 34.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock worth $43,357,000 after purchasing an additional 525,369 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of 10x Genomics during the 1st quarter worth $5,945,000. Swiss National Bank boosted its position in shares of 10x Genomics by 2.2% during the 1st quarter. Swiss National Bank now owns 207,400 shares of the company’s stock worth $4,403,000 after purchasing an additional 4,400 shares in the last quarter. Finally, Voya Investment Management LLC grew its stake in shares of 10x Genomics by 6.2% during the 3rd quarter. Voya Investment Management LLC now owns 130,595 shares of the company’s stock worth $11,801,000 after purchasing an additional 7,680 shares during the period. Hedge funds and other institutional investors own 84.68% of the company’s stock.
Insider Buying and Selling at 10x Genomics
In related news, CEO Serge Saxonov sold 31,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $62.90, for a total transaction of $1,949,900.00. Following the transaction, the chief executive officer owned 1,019,249 shares of the company’s stock, valued at approximately $64,110,762.10. This represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John R. Stuelpnagel sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the transaction, the director directly owned 328,436 shares in the company, valued at $20,280,923. The trade was a 5.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 190,333 shares of company stock valued at $12,604,970. Corporate insiders own 8.84% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on the stock. TD Cowen increased their price target on shares of 10x Genomics from $47.00 to $70.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Piper Sandler boosted their price objective on shares of 10x Genomics from $47.00 to $80.00 and gave the stock a “neutral” rating in a report on Monday, September 28th. Canaccord Genuity Group boosted their price objective on shares of 10x Genomics from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Stifel Nicolaus upped their target price on shares of 10x Genomics from $50.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Finally, Citigroup increased their target price on shares of 10x Genomics from $50.00 to $60.00 and gave the company a “hold” rating in a report on Friday, November 6th. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and a consensus target price of $68.40.
Read Our Latest Analysis on TXG
10x Genomics Stock Up 0.5%
TXG opened at $57.38 on Friday. The firm has a market cap of $7.55 billion, a P/E ratio of -110.35 and a beta of 2.03. 10x Genomics has a 52 week low of $15.18 and a 52 week high of $102.81. The business’s fifty day simple moving average is $73.20 and its 200 day simple moving average is $43.29.
10x Genomics (NASDAQ:TXG – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. The firm had revenue of $150.67 million during the quarter, compared to the consensus estimate of $147.96 million. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.22) EPS. As a group, equities analysts expect that 10x Genomics will post -0.67 EPS for the current fiscal year.
10x Genomics Profile
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Recommended Stories
- Five stocks we like better than 10x Genomics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
